ID   K2C8_HUMAN              Reviewed;         483 AA.
AC   P05787; A8K4H3; B0AZN5; F8VXB4; Q14099; Q14716; Q14717; Q53GJ0;
AC   Q6DHW5; Q6GMY0; Q6P4C7; Q96J60;
DT   01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 7.
DT   28-FEB-2018, entry version 215.
DE   RecName: Full=Keratin, type II cytoskeletal 8;
DE   AltName: Full=Cytokeratin-8;
DE            Short=CK-8;
DE   AltName: Full=Keratin-8;
DE            Short=K8;
DE   AltName: Full=Type-II keratin Kb8;
GN   Name=KRT8; Synonyms=CYK8;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLY-417.
RX   PubMed=1691124; DOI=10.1016/0378-1119(90)90285-Y;
RA   Krauss S., Franke W.W.;
RT   "Organization and sequence of the human gene encoding cytokeratin 8.";
RL   Gene 86:241-249(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1692965; DOI=10.1210/mend-4-3-370;
RA   Yamamoto R., Kao L.C., McKnight C.E., Strauss J.F. III;
RT   "Cloning and sequence of cDNA for human placental cytokeratin 8.
RT   Regulation of the mRNA in trophoblastic cells by cAMP.";
RL   Mol. Endocrinol. 4:370-374(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=1705144;
RA   Waseem A., Alexander C.M., Steel J.B., Lane E.B.;
RT   "Embryonic simple epithelial keratins 8 and 18: chromosomal location
RT   emphasizes difference from other keratin pairs.";
RL   New Biol. 2:464-478(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PHOSPHORYLATION AT SER-24
RP   AND SER-432.
RX   PubMed=9054461; DOI=10.1074/jbc.272.11.7556;
RA   Ku N.-O., Omary M.B.;
RT   "Phosphorylation of human keratin 8 in vivo at conserved head domain
RT   serine 23 and at epidermal growth factor-stimulated tail domain serine
RT   431.";
RL   J. Biol. Chem. 272:7556-7564(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Kidney;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   CYS-62.
RC   TISSUE=Colon, Liver, Lung, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-231 (ISOFORM 1).
RX   PubMed=2471065; DOI=10.1128/MCB.9.4.1553;
RA   Kulesh D.A., Cecena G., Darmon Y.M., Vasseur M., Oshima R.G.;
RT   "Posttranslational regulation of keratins: degradation of mouse and
RT   human keratins 18 and 8.";
RL   Mol. Cell. Biol. 9:1553-1565(1989).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 205-483 (ISOFORM 1), AND VARIANTS
RP   GLY-417 AND ASP-429.
RX   PubMed=2434381; DOI=10.1111/j.1432-0436.1986.tb00412.x;
RA   Leube R.E., Bosch F.X., Romano V., Zimbelmann R., Hofler H.,
RA   Franke W.W.;
RT   "Cytokeratin expression in simple epithelia. III. Detection of mRNAs
RT   encoding human cytokeratins nos. 8 and 18 in normal and tumor cells by
RT   hybridization with cDNA sequences in vitro and in situ.";
RL   Differentiation 33:69-85(1986).
RN   [12]
RP   PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Colon carcinoma;
RX   PubMed=9150948; DOI=10.1002/elps.1150180344;
RA   Ji H., Reid G.E., Moritz R.L., Eddes J.S., Burgess A.W., Simpson R.J.;
RT   "A two-dimensional gel database of human colon carcinoma proteins.";
RL   Electrophoresis 18:605-613(1997).
RN   [13]
RP   GLYCOSYLATION.
RX   PubMed=1371281;
RA   Chou C.F., Smith A.J., Omary M.B.;
RT   "Characterization and dynamics of O-linked glycosylation of human
RT   cytokeratin 8 and 18.";
RL   J. Biol. Chem. 267:3901-3906(1992).
RN   [14]
RP   PHOSPHORYLATION AT SER-9 AND SER-24.
RX   PubMed=1374067; DOI=10.1083/jcb.117.3.583;
RA   Omary M.B., Baxter G.T., Chou C.F., Riopel C.L., Lin W.Y.,
RA   Strulovici B.;
RT   "PKC epsilon-related kinase associates with and phosphorylates
RT   cytokeratin 8 and 18.";
RL   J. Cell Biol. 117:583-593(1992).
RN   [15]
RP   INTERACTION WITH KRT20, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=10973561; DOI=10.1016/S0003-9969(00)00050-9;
RA   Barrett A.W., Cort E.M., Patel P., Berkovitz B.K.B.;
RT   "An immunohistological study of cytokeratin 20 in human and mammalian
RT   oral epithelium.";
RL   Arch. Oral Biol. 45:879-887(2000).
RN   [16]
RP   INTERACTION WITH PNN.
RX   PubMed=10809736; DOI=10.1074/jbc.275.20.14910;
RA   Shi J., Sugrue S.P.;
RT   "Dissection of protein linkage between keratins and pinin, a protein
RT   with dual location at desmosome-intermediate filament complex and in
RT   the nucleus.";
RL   J. Biol. Chem. 275:14910-14915(2000).
RN   [17]
RP   PHOSPHORYLATION AT SER-74.
RX   PubMed=11781324; DOI=10.1074/jbc.M111436200;
RA   He T., Stepulak A., Holmstrom T.H., Omary M.B., Eriksson J.E.;
RT   "The intermediate filament protein keratin 8 is a novel cytoplasmic
RT   substrate for c-Jun N-terminal kinase.";
RL   J. Biol. Chem. 277:10767-10774(2002).
RN   [18]
RP   PHOSPHORYLATION AT SER-74, AND MUTAGENESIS OF LEU-72 AND SER-74.
RX   PubMed=11788583; DOI=10.1074/jbc.M107623200;
RA   Ku N.O., Azhar S., Omary M.B.;
RT   "Keratin 8 phosphorylation by p38 kinase regulates cellular keratin
RT   filament reorganization: modulation by a keratin 1-like disease
RT   causing mutation.";
RL   J. Biol. Chem. 277:10775-10782(2002).
RN   [19]
RP   INTERACTION WITH TCHP.
RX   PubMed=15731013; DOI=10.1242/jcs.01667;
RA   Nishizawa M., Izawa I., Inoko A., Hayashi Y., Nagata K., Yokoyama T.,
RA   Usukura J., Inagaki M.;
RT   "Identification of trichoplein, a novel keratin filament-binding
RT   protein.";
RL   J. Cell Sci. 118:1081-1090(2005).
RN   [20]
RP   FUNCTION, SUBUNIT, AND TISSUE SPECIFICITY.
RX   PubMed=16000376; DOI=10.1091/mbc.E05-02-0112;
RA   Stone M.R., O'Neill A., Catino D., Bloch R.J.;
RT   "Specific interaction of the actin-binding domain of dystrophin with
RT   intermediate filaments containing keratin 19.";
RL   Mol. Biol. Cell 16:4280-4293(2005).
RN   [21]
RP   INTERACTION WITH HCV CORE PROTEIN.
RX   PubMed=15846844; DOI=10.1002/pmic.200401093;
RA   Kang S.-M., Shin M.-J., Kim J.-H., Oh J.-W.;
RT   "Proteomic profiling of cellular proteins interacting with the
RT   hepatitis C virus core protein.";
RL   Proteomics 5:2227-2237(2005).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-253 AND SER-330, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [23]
RP   INTERACTION WITH KRT20.
RX   PubMed=16608857; DOI=10.1074/jbc.M512284200;
RA   Zhou Q., Cadrin M., Herrmann H., Chen C.-H., Chalkley R.J.,
RA   Burlingame A.L., Omary M.B.;
RT   "Keratin 20 serine 13 phosphorylation is a stress and intestinal
RT   goblet cell marker.";
RL   J. Biol. Chem. 281:16453-16461(2006).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-253 AND SER-258, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21; SER-24; SER-27;
RP   SER-43; SER-253; SER-258; SER-274; SER-400; SER-410; SER-432; SER-475
RP   AND SER-478, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [27]
RP   INTERACTION WITH APEX1, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=19188445; DOI=10.1128/MCB.01337-08;
RA   Vascotto C., Fantini D., Romanello M., Cesaratto L., Deganuto M.,
RA   Leonardi A., Radicella J.P., Kelley M.R., D'Ambrosio C., Scaloni A.,
RA   Quadrifoglio F., Tell G.;
RT   "APE1/Ref-1 interacts with NPM1 within nucleoli and plays a role in
RT   the rRNA quality control process.";
RL   Mol. Cell. Biol. 29:1834-1854(2009).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-253, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [29]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-207; LYS-295 AND LYS-325,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [30]
RP   GLYCOSYLATION.
RX   PubMed=20729549; DOI=10.1074/jbc.M109.098996;
RA   Srikanth B., Vaidya M.M., Kalraiya R.D.;
RT   "O-GlcNAcylation determines the solubility, filament organization, and
RT   stability of keratins 8 and 18.";
RL   J. Biol. Chem. 285:34062-34071(2010).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-228; SER-475 AND
RP   SER-478, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [32]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [33]
RP   MALONYLATION AT LYS-101.
RX   PubMed=21908771; DOI=10.1074/mcp.M111.012658;
RA   Peng C., Lu Z., Xie Z., Cheng Z., Chen Y., Tan M., Luo H., Zhang Y.,
RA   He W., Yang K., Zwaans B.M., Tishkoff D., Ho L., Lombard D., He T.C.,
RA   Dai J., Verdin E., Ye Y., Zhao Y.;
RT   "The first identification of lysine malonylation substrates and its
RT   regulatory enzyme.";
RL   Mol. Cell. Proteomics 10:M111.012658.01-M111.012658.12(2011).
RN   [34]
RP   INTERACTION WITH GPER1.
RX   PubMed=21149639; DOI=10.1124/mol.110.069500;
RA   Sanden C., Broselid S., Cornmark L., Andersson K.,
RA   Daszkiewicz-Nilsson J., Martensson U.E., Olde B., Leeb-Lundberg L.M.;
RT   "G protein-coupled estrogen receptor 1/G protein-coupled receptor 30
RT   localizes in the plasma membrane and traffics intracellularly on
RT   cytokeratin intermediate filaments.";
RL   Mol. Pharmacol. 79:400-410(2011).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-24; SER-43; SER-253 AND
RP   SER-258, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [36]
RP   GLYCOSYLATION.
RX   PubMed=22967762; DOI=10.1016/j.bbagen.2012.08.024;
RA   Drougat L., Olivier-Van Stichelen S., Mortuaire M., Foulquier F.,
RA   Lacoste A.S., Michalski J.C., Lefebvre T., Vercoutter-Edouart A.S.;
RT   "Characterization of O-GlcNAc cycling and proteomic identification of
RT   differentially O-GlcNAcylated proteins during G1/S transition.";
RL   Biochim. Biophys. Acta 1820:1839-1848(2012).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-13; SER-21; SER-31;
RP   SER-34; SER-39; SER-43; SER-253; SER-258; SER-274; SER-291; SER-330;
RP   SER-404; SER-410; SER-475 AND SER-477, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-15; SER-22; SER-253;
RP   SER-258; SER-410 AND SER-475, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [39]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-23; ARG-32; ARG-40 AND
RP   ARG-47, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.O113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V.,
RA   Aguiar M., Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C.,
RA   Vemulapalli V., Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [40]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-285; LYS-304 AND LYS-472,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [41]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-197; LYS-285 AND LYS-472,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [42]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-11; LYS-122; LYS-130;
RP   LYS-197; LYS-264; LYS-285; LYS-295; LYS-304; LYS-325; LYS-393 AND
RP   LYS-472, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-
RT   modification with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [43]
RP   VARIANTS CIRRH VAL-53; CYS-54 AND CYS-62, AND VARIANT VAL-63.
RX   PubMed=12724528; DOI=10.1073/pnas.0936165100;
RA   Ku N.-O., Darling J.M., Krams S.M., Esquivel C.O., Keeffe E.B.,
RA   Sibley R.K., Lee Y.M., Wright T.L., Omary M.B.;
RT   "Keratin 8 and 18 mutations are risk factors for developing liver
RT   disease of multiple etiologies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:6063-6068(2003).
CC   -!- FUNCTION: Together with KRT19, helps to link the contractile
CC       apparatus to dystrophin at the costameres of striated muscle.
CC       {ECO:0000269|PubMed:16000376}.
CC   -!- SUBUNIT: Heterotetramer of two type I and two type II keratins.
CC       KRT8 associates with KRT18. Associates with KRT20. Interacts with
CC       HCV core protein and PNN. When associated with KRT19, interacts
CC       with DMD. Interacts with TCHP. Interacts with APEX1. Interacts
CC       with GPER1. Interacts with EPPK1 (By similarity).
CC       {ECO:0000250|UniProtKB:P11679, ECO:0000269|PubMed:10809736,
CC       ECO:0000269|PubMed:10973561, ECO:0000269|PubMed:15731013,
CC       ECO:0000269|PubMed:15846844, ECO:0000269|PubMed:16000376,
CC       ECO:0000269|PubMed:16608857, ECO:0000269|PubMed:19188445,
CC       ECO:0000269|PubMed:21149639}.
CC   -!- INTERACTION:
CC       P13569:CFTR; NbExp=7; IntAct=EBI-297852, EBI-349854;
CC       P62993:GRB2; NbExp=3; IntAct=EBI-297852, EBI-401755;
CC       Q9Y6K9:IKBKG; NbExp=2; IntAct=EBI-297852, EBI-81279;
CC       A1A4E9:KRT13; NbExp=3; IntAct=EBI-297852, EBI-10171552;
CC       P19012:KRT15; NbExp=5; IntAct=EBI-297852, EBI-739566;
CC       P05783:KRT18; NbExp=12; IntAct=EBI-297852, EBI-297888;
CC       P08727:KRT19; NbExp=4; IntAct=EBI-297852, EBI-742756;
CC       Q7Z3Y7:KRT28; NbExp=4; IntAct=EBI-297852, EBI-11980489;
CC       Q15323:KRT31; NbExp=5; IntAct=EBI-297852, EBI-948001;
CC       O76015:KRT38; NbExp=5; IntAct=EBI-297852, EBI-1047263;
CC       Q6A162:KRT40; NbExp=5; IntAct=EBI-297852, EBI-10171697;
CC       O75022:LILRB3; NbExp=3; IntAct=EBI-297852, EBI-2830524;
CC       Q13835-2:PKP1; NbExp=3; IntAct=EBI-297852, EBI-9087684;
CC       P14079:tax (xeno); NbExp=3; IntAct=EBI-297852, EBI-9675698;
CC       Q9UBB9:TFIP11; NbExp=3; IntAct=EBI-297852, EBI-1105213;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10973561,
CC       ECO:0000269|PubMed:19188445}. Nucleus, nucleoplasm {ECO:0000250}.
CC       Nucleus matrix {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P05787-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P05787-2; Sequence=VSP_046000;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Observed in muscle fibers accumulating in the
CC       costameres of myoplasm at the sarcolemma membrane in structures
CC       that contain dystrophin and spectrin. Expressed in gingival mucosa
CC       and hard palate of the oral cavity. {ECO:0000269|PubMed:10973561,
CC       ECO:0000269|PubMed:16000376}.
CC   -!- PTM: Phosphorylation on serine residues is enhanced during EGF
CC       stimulation and mitosis. Ser-74 phosphorylation plays an important
CC       role in keratin filament reorganization.
CC       {ECO:0000269|PubMed:11781324, ECO:0000269|PubMed:11788583,
CC       ECO:0000269|PubMed:1374067, ECO:0000269|PubMed:9054461}.
CC   -!- PTM: O-glycosylated. O-GlcNAcylation at multiple sites increases
CC       solubility, and decreases stability by inducing proteasomal
CC       degradation.
CC   -!- PTM: O-glycosylated (O-GlcNAcylated), in a cell cycle-dependent
CC       manner.
CC   -!- DISEASE: Cirrhosis (CIRRH) [MIM:215600]: A liver disease
CC       characterized by severe panlobular liver-cell swelling with
CC       Mallory body formation, prominent pericellular fibrosis, and
CC       marked deposits of copper. Clinical features include abdomen
CC       swelling, jaundice and pulmonary hypertension.
CC       {ECO:0000269|PubMed:12724528}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: There are two types of cytoskeletal and
CC       microfibrillar keratin: I (acidic; 40-55 kDa) and II (neutral to
CC       basic; 56-70 kDa).
CC   -!- SIMILARITY: Belongs to the intermediate filament family.
CC       {ECO:0000255|PROSITE-ProRule:PRU01188}.
CC   -!- WEB RESOURCE: Name=Human Intermediate Filament Mutation Database;
CC       URL="http://www.interfil.org";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M34482; AAA35763.1; -; Genomic_DNA.
DR   EMBL; M34225; AAA35748.1; -; mRNA.
DR   EMBL; X74929; CAA52882.1; -; mRNA.
DR   EMBL; X74981; CAA52916.1; -; Genomic_DNA.
DR   EMBL; U76549; AAB18966.1; -; mRNA.
DR   EMBL; AK290938; BAF83627.1; -; mRNA.
DR   EMBL; AK310257; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK315826; BAF98717.1; -; mRNA.
DR   EMBL; AK222941; BAD96661.1; -; mRNA.
DR   EMBL; AC107016; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471054; EAW96653.1; -; Genomic_DNA.
DR   EMBL; BC000654; AAH00654.3; -; mRNA.
DR   EMBL; BC063513; AAH63513.2; -; mRNA.
DR   EMBL; BC073760; AAH73760.1; -; mRNA.
DR   EMBL; BC075839; AAH75839.1; -; mRNA.
DR   EMBL; M26512; AAA51542.1; -; mRNA.
DR   EMBL; X12882; CAA31376.1; -; mRNA.
DR   EMBL; X98614; CAA67203.1; -; mRNA.
DR   CCDS; CCDS58234.1; -. [P05787-2]
DR   CCDS; CCDS8841.1; -. [P05787-1]
DR   PIR; A34720; A34720.
DR   RefSeq; NP_001243222.1; NM_001256293.1. [P05787-1]
DR   RefSeq; NP_002264.1; NM_002273.3. [P05787-1]
DR   UniGene; Hs.533782; -.
DR   UniGene; Hs.708445; -.
DR   ProteinModelPortal; P05787; -.
DR   SMR; P05787; -.
DR   BioGrid; 110054; 58.
DR   DIP; DIP-424N; -.
DR   ELM; P05787; -.
DR   IntAct; P05787; 47.
DR   MINT; P05787; -.
DR   STRING; 9606.ENSP00000293308; -.
DR   DrugBank; DB00031; Tenecteplase.
DR   iPTMnet; P05787; -.
DR   PhosphoSitePlus; P05787; -.
DR   SwissPalm; P05787; -.
DR   UniCarbKB; P05787; -.
DR   BioMuta; KRT8; -.
DR   DMDM; 90110027; -.
DR   SWISS-2DPAGE; P05787; -.
DR   EPD; P05787; -.
DR   PaxDb; P05787; -.
DR   PeptideAtlas; P05787; -.
DR   PRIDE; P05787; -.
DR   TopDownProteomics; P05787-1; -. [P05787-1]
DR   TopDownProteomics; P05787-2; -. [P05787-2]
DR   DNASU; 3856; -.
DR   Ensembl; ENST00000293308; ENSP00000293308; ENSG00000170421. [P05787-1]
DR   Ensembl; ENST00000546897; ENSP00000447402; ENSG00000170421. [P05787-1]
DR   Ensembl; ENST00000552150; ENSP00000449404; ENSG00000170421. [P05787-2]
DR   Ensembl; ENST00000552551; ENSP00000447566; ENSG00000170421. [P05787-1]
DR   GeneID; 3856; -.
DR   KEGG; hsa:3856; -.
DR   UCSC; uc001sbd.3; human. [P05787-1]
DR   CTD; 3856; -.
DR   DisGeNET; 3856; -.
DR   EuPathDB; HostDB:ENSG00000170421.12; -.
DR   GeneCards; KRT8; -.
DR   H-InvDB; HIX0026255; -.
DR   H-InvDB; HIX0034365; -.
DR   H-InvDB; HIX0168895; -.
DR   HGNC; HGNC:6446; KRT8.
DR   HPA; CAB000131; -.
DR   HPA; CAB001696; -.
DR   HPA; HPA049866; -.
DR   MalaCards; KRT8; -.
DR   MIM; 148060; gene.
DR   MIM; 215600; phenotype.
DR   neXtProt; NX_P05787; -.
DR   OpenTargets; ENSG00000170421; -.
DR   PharmGKB; PA30234; -.
DR   eggNOG; ENOG410IG4R; Eukaryota.
DR   eggNOG; ENOG410YY6B; LUCA.
DR   GeneTree; ENSGT00760000118796; -.
DR   HOVERGEN; HBG013015; -.
DR   InParanoid; P05787; -.
DR   KO; K07605; -.
DR   OMA; IQKRTDM; -.
DR   OrthoDB; EOG091G09KR; -.
DR   PhylomeDB; P05787; -.
DR   TreeFam; TF317854; -.
DR   Reactome; R-HSA-6805567; Keratinization.
DR   Reactome; R-HSA-6809371; Formation of the cornified envelope.
DR   SignaLink; P05787; -.
DR   SIGNOR; P05787; -.
DR   ChiTaRS; KRT8; human.
DR   GeneWiki; Keratin_8; -.
DR   GenomeRNAi; 3856; -.
DR   PMAP-CutDB; P05787; -.
DR   PRO; PR:P05787; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000170421; -.
DR   ExpressionAtlas; P05787; baseline and differential.
DR   Genevisible; P05787; HS.
DR   GO; GO:0016327; C:apicolateral plasma membrane; IEA:Ensembl.
DR   GO; GO:0005911; C:cell-cell junction; IEA:Ensembl.
DR   GO; GO:0043034; C:costamere; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016010; C:dystrophin-associated glycoprotein complex; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005882; C:intermediate filament; IDA:BHF-UCL.
DR   GO; GO:0045111; C:intermediate filament cytoskeleton; IDA:HPA.
DR   GO; GO:0045095; C:keratin filament; IEA:Ensembl.
DR   GO; GO:0016363; C:nuclear matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; HDA:UniProtKB.
DR   GO; GO:0042383; C:sarcolemma; IEA:Ensembl.
DR   GO; GO:0030018; C:Z disc; IEA:Ensembl.
DR   GO; GO:0032403; F:protein complex binding; IEA:Ensembl.
DR   GO; GO:0097110; F:scaffold protein binding; IPI:BHF-UCL.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0060706; P:cell differentiation involved in embryonic placenta development; IEA:Ensembl.
DR   GO; GO:0070268; P:cornification; TAS:Reactome.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0097284; P:hepatocyte apoptotic process; IEA:Ensembl.
DR   GO; GO:0031424; P:keratinization; TAS:Reactome.
DR   GO; GO:0051599; P:response to hydrostatic pressure; IEA:Ensembl.
DR   GO; GO:0051707; P:response to other organism; IEA:Ensembl.
DR   GO; GO:0045214; P:sarcomere organization; IEA:Ensembl.
DR   GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   InterPro; IPR001664; IF.
DR   InterPro; IPR018039; Intermediate_filament_CS.
DR   InterPro; IPR032444; Keratin_2_head.
DR   InterPro; IPR003054; Keratin_II.
DR   PANTHER; PTHR23239; PTHR23239; 1.
DR   Pfam; PF00038; Filament; 1.
DR   Pfam; PF16208; Keratin_2_head; 1.
DR   PRINTS; PR01276; TYPE2KERATIN.
DR   SMART; SM01391; Filament; 1.
DR   PROSITE; PS00226; IF_ROD_1; 1.
DR   PROSITE; PS51842; IF_ROD_2; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Coiled coil; Complete proteome;
KW   Cytoplasm; Direct protein sequencing; Disease mutation; Glycoprotein;
KW   Host-virus interaction; Intermediate filament; Isopeptide bond;
KW   Keratin; Methylation; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Ubl conjugation.
FT   CHAIN         1    483       Keratin, type II cytoskeletal 8.
FT                                /FTId=PRO_0000063740.
FT   DOMAIN       91    402       IF rod. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01188}.
FT   REGION        1     90       Head.
FT   REGION       91    126       Coil 1A.
FT   REGION      127    143       Linker 1.
FT   REGION      144    235       Coil 1B.
FT   REGION      236    259       Linker 12.
FT   REGION      260    398       Coil 2.
FT   REGION      261    382       Necessary for interaction with PNN.
FT                                {ECO:0000269|PubMed:10809736}.
FT   REGION      399    483       Tail.
FT   COMPBIAS      9     49       Ser-rich.
FT   SITE        342    342       Stutter.
FT   MOD_RES       9      9       Phosphoserine; by PKC/PRKCE.
FT                                {ECO:0000269|PubMed:1374067}.
FT   MOD_RES      13     13       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      15     15       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES      21     21       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      22     22       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES      23     23       Omega-N-methylarginine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES      24     24       Phosphoserine; by PKC/PRKCE.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000269|PubMed:1374067,
FT                                ECO:0000269|PubMed:9054461}.
FT   MOD_RES      26     26       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q10758}.
FT   MOD_RES      27     27       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES      31     31       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      32     32       Omega-N-methylarginine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES      34     34       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      37     37       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q10758}.
FT   MOD_RES      39     39       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      40     40       Omega-N-methylarginine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES      43     43       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      44     44       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q10758}.
FT   MOD_RES      47     47       Asymmetric dimethylarginine; alternate.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES      47     47       Omega-N-methylarginine; alternate.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES      74     74       Phosphoserine; by MAPK.
FT                                {ECO:0000269|PubMed:11781324,
FT                                ECO:0000269|PubMed:11788583}.
FT   MOD_RES     101    101       N6-malonyllysine.
FT                                {ECO:0000269|PubMed:21908771}.
FT   MOD_RES     207    207       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     228    228       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES     253    253       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     258    258       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     274    274       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     291    291       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     295    295       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     325    325       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     330    330       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     400    400       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     404    404       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     410    410       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     417    417       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q10758}.
FT   MOD_RES     424    424       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q10758}.
FT   MOD_RES     432    432       Phosphoserine; by CaMK2 and MAPK.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000269|PubMed:9054461}.
FT   MOD_RES     475    475       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     477    477       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     478    478       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231}.
FT   CROSSLNK     11     11       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    122    122       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    130    130       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    197    197       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1);
FT                                alternate. {ECO:0000244|PubMed:25114211}.
FT   CROSSLNK    197    197       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2);
FT                                alternate. {ECO:0000244|PubMed:25114211,
FT                                ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    264    264       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    285    285       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25114211,
FT                                ECO:0000244|PubMed:25218447,
FT                                ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    295    295       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2);
FT                                alternate. {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    304    304       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25218447,
FT                                ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    325    325       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2);
FT                                alternate. {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    393    393       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    472    472       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1);
FT                                alternate. {ECO:0000244|PubMed:25114211}.
FT   CROSSLNK    472    472       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2);
FT                                alternate. {ECO:0000244|PubMed:25114211,
FT                                ECO:0000244|PubMed:25218447,
FT                                ECO:0000244|PubMed:28112733}.
FT   VAR_SEQ       1      1       M -> MNGVSWSQDLQEGISAWFGPPASTPASTM (in
FT                                isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_046000.
FT   VARIANT      53     53       G -> V (in CIRRH; dbSNP:rs61710484).
FT                                {ECO:0000269|PubMed:12724528}.
FT                                /FTId=VAR_023058.
FT   VARIANT      54     54       Y -> C (in CIRRH).
FT                                {ECO:0000269|PubMed:12724528}.
FT                                /FTId=VAR_023059.
FT   VARIANT      62     62       G -> C (in CIRRH; dbSNP:rs11554495).
FT                                {ECO:0000269|PubMed:12724528,
FT                                ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_023060.
FT   VARIANT      63     63       I -> V (in dbSNP:rs59536457).
FT                                {ECO:0000269|PubMed:12724528}.
FT                                /FTId=VAR_023061.
FT   VARIANT     401    401       R -> W (in dbSNP:rs2277330).
FT                                /FTId=VAR_049805.
FT   VARIANT     417    417       S -> G. {ECO:0000269|PubMed:1691124,
FT                                ECO:0000269|PubMed:2434381}.
FT                                /FTId=VAR_069106.
FT   VARIANT     429    429       G -> D (in dbSNP:rs1065648).
FT                                {ECO:0000269|PubMed:2434381}.
FT                                /FTId=VAR_069107.
FT   MUTAGEN      72     72       L->P: Increases phosphorylation.
FT                                {ECO:0000269|PubMed:11788583}.
FT   MUTAGEN      74     74       S->A: Generates normal-appearing
FT                                filaments, that remain stable after
FT                                okadaic acid treatment.
FT                                {ECO:0000269|PubMed:11788583}.
FT   MUTAGEN      74     74       S->D: Generates normal-appearing
FT                                filaments, that are destabilized by
FT                                okadaic acid.
FT                                {ECO:0000269|PubMed:11788583}.
FT   CONFLICT     56     56       G -> V (in Ref. 5; BAF83627).
FT                                {ECO:0000305}.
FT   CONFLICT     77     77       V -> S (in Ref. 2; AAA35748).
FT                                {ECO:0000305}.
FT   CONFLICT    201    201       D -> DVD (in Ref. 3; CAA52882).
FT                                {ECO:0000305}.
FT   CONFLICT    232    232       I -> L (in Ref. 11; CAA67203).
FT                                {ECO:0000305}.
FT   CONFLICT    257    257       D -> E (in Ref. 2; AAA35748).
FT                                {ECO:0000305}.
FT   CONFLICT    310    310       M -> I (in Ref. 11; CAA31376).
FT                                {ECO:0000305}.
FT   CONFLICT    324    324       L -> F (in Ref. 6; BAD96661).
FT                                {ECO:0000305}.
FT   CONFLICT    384    384       L -> M (in Ref. 11; CAA67203).
FT                                {ECO:0000305}.
FT   CONFLICT    387    387       E -> D (in Ref. 2; AAA35748).
FT                                {ECO:0000305}.
FT   CONFLICT    401    401       R -> P (in Ref. 2; AAA35748).
FT                                {ECO:0000305}.
FT   CONFLICT    430    433       LTSP -> SQA (in Ref. 1; AAA35763).
FT                                {ECO:0000305}.
FT   CONFLICT    431    431       T -> A (in Ref. 11; CAA67203).
FT                                {ECO:0000305}.
FT   CONFLICT    432    432       S -> D (in Ref. 2; AAA35748 and 11;
FT                                CAA67203/CAA31376). {ECO:0000305}.
SQ   SEQUENCE   483 AA;  53704 MW;  B0BC730B65929D37 CRC64;
     MSIRVTQKSY KVSTSGPRAF SSRSYTSGPG SRISSSSFSR VGSSNFRGGL GGGYGGASGM
     GGITAVTVNQ SLLSPLVLEV DPNIQAVRTQ EKEQIKTLNN KFASFIDKVR FLEQQNKMLE
     TKWSLLQQQK TARSNMDNMF ESYINNLRRQ LETLGQEKLK LEAELGNMQG LVEDFKNKYE
     DEINKRTEME NEFVLIKKDV DEAYMNKVEL ESRLEGLTDE INFLRQLYEE EIRELQSQIS
     DTSVVLSMDN SRSLDMDSII AEVKAQYEDI ANRSRAEAES MYQIKYEELQ SLAGKHGDDL
     RRTKTEISEM NRNISRLQAE IEGLKGQRAS LEAAIADAEQ RGELAIKDAN AKLSELEAAL
     QRAKQDMARQ LREYQELMNV KLALDIEIAT YRKLLEGEES RLESGMQNMS IHTKTTSGYA
     GGLSSAYGGL TSPGLSYSLG SSFGSGAGSS SFSRTSSSRA VVVKKIETRD GKLVSESSDV
     LPK
//
